Capstan Therapeutics vs Neuralink
Side-by-side comparison of AI visibility scores, market position, and capabilities
Capstan Therapeutics develops in vivo RNA-based therapies using targeted lipid nanoparticles to engineer immune cells inside the body without ex vivo manufacturing; raised $165M Series A in 2022; targeting oncology, fibrosis, and autoimmune diseases.
About
Capstan Therapeutics is a biopharmaceutical company founded in 2021 and headquartered in Philadelphia, Pennsylvania, with scientific co-founders including Drew Weissman (2023 Nobel Prize in Medicine laureate for mRNA technology) and Carl June (pioneer of CAR-T cell therapy). The company is developing a novel class of in vivo RNA-based medicines that use targeted lipid nanoparticles (LNPs) to deliver genetic instructions directly into specific immune cells inside the patient's body — enabling the creation of therapeutic immune cells (similar to CAR-T cells) without the costly and time-consuming ex vivo manufacturing process that currently requires extracting, engineering, and re-infusing a patient's cells outside the body.
Pioneer of implantable BCIs with 12+ active human patients as of Sep 2025; raised $650M Series E in Apr 2026 led by ARK Invest and Sequoia at a ~$14.9B valuation; mass production underway.
About
Neuralink is a neurotechnology company founded in 2016 by Elon Musk and a team of neuroscientists and engineers, developing implantable brain-computer interface devices that enable individuals with paralysis to control digital devices directly with their thoughts. The company's first commercial product, the N1 implant, is a coin-sized device containing 1,024 electrodes that is surgically placed in the motor cortex. As of September 2025, twelve patients worldwide had received the N1 implant and were actively using it to control computers, smartphones, and robotic arms with neural signals alone.
Key Details
Also Compare
Track AI Visibility in Real Time
Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.